High-throughput assays are important biological research tools but are rarely utilised for platelet research. However, screening compounds for efficacy against a physiologically relevant cellular response in primary cells such as platelets can be an advantageous approach to compound screening and drug development. In this section we describe a panel of three high-throughput microtitre plate assays designed for platelets that can be used as the basis for compound screening, or be modified and used individually to increase throughput in platelet research labs. The platelet adhesion assay has the lowest requirement for platelet numbers and is therefore capable of the greatest throughput and so is suggested as the primary screen used to identify hits. A second screen against the 'gold standard' of platelet function, aggregation, is used to confirm and further characterise hits.
Introduction
Screening on the basis of clinically relevant functions using primary cells is referred to as physiological or phenotypic screening [1] and, by identifying compounds that exert a desired clinical effect on a target tissue, bypasses the need for initial target identification and screening using a cell line expressing a target protein [2] . Two functions of platelets that are relevant to their roles in thrombosis and haemostasis are their ability to adhere to proteins of the subendothelial matrix and to form aggregates. Mechanistic characterisation of compounds that are able to modulate these platelet functions should follow 'hit' identification to elucidate their mode of action. Cytosolic Ca 2+ is a master regulator of platelet function and is common to nearly all platelet signalling pathways [3] and is therefore a versatile signalling output that can be used for initial mechanistic characterisation.
This chapter describes a panel of high-throughput techniques to characterise the effects of compounds on three aspects of platelet function; adhesion, aggregation and Ca 2+ signalling. The miniaturised platelet assays measure these outputs in microtiter plates and may be applied in sequence to screen compound libraries and to give comprehensive characterisation of 'hits' that modulate platelet function. Alternatively, the methods may be adapted and utilised individually to reduce costs, increase throughput and facilitate a pharmacological approach to platelet research.
Platelet adhesion assays are commonly performed on glass coverslips coated in matrix proteins such as collagen. Our approach utilises 96-well microtitre plates, but the assay could easily be miniaturised for use in 384-well plates given the correct setup. The rationale behind using the platelet adhesion assay as the primary high-throughput screening test is the very low number of platelets required per test, at 1e 6 platelets per well in a half-area 96-well plate or just 5e 5 per well of a 384-well plate. Such low requirements are conducive to screening of compound libraries that may contain thousands of molecules. The challenges of the approach lie in data collection and analysis, as every well must be imaged and analysed to give a quantitative output of platelet adhesion and morphology. However, automated imaging platforms and bespoke analysis packages are now common and so capturing and analysing thousands of images is no longer the insurmountable challenge it once was.
Platelet aggregometry has remained the gold standard in platelet function testing since the method was published by Gustav Born in 1963 [4] . Our plate-based aggregation assay was adapted from the method published by Lordkipanidze et al [5] and gives only an end-point measurement rather than the real-time aggregation trace generated by Born aggregometry. This means that only a single value is generated per condition tested giving a simplistic but easily interpretable read-out of platelet aggregation. Two advantages of the plate-based aggregation assay are that both the assay itself and the analysis are extremely quick.
Ca 2+ is a master regulator of platelet function, indeed elevation of cytosolic [Ca 2+ ] is mediated downstream of almost all platelet activators and so it is also a point of signal integration.
Measurement of cytosolic Ca 2+ is a commonly utilised assay tool within the pharmaceutical industry and so specialised plate readers with automated liquid handling are similarly well established and also achieve good results when used to assay platelet responses. Our assay utilises half-area 96-well microtitre plates, but systems that enable rapid measurements of 384-well plates are also compatible with screening platelet responses. Ca 2+ measurements are performed in real time and are therefore potentially more time consuming than other techniques described in this chapter. However, real time Ca 2+ measurements reveal details of signalling dynamics that may be useful and can be used to inform quantitative systems pharmacology.
High-throughput methodologies are increasingly being adopted within academia and while few academic labs have access to robotics and automated systems, facilities have been established that can give academic researchers access to high-throughput screening (HTS) platforms, compound libraries and specialists with expertise in HTS [6] . In addition to compound screening high throughput methodologies facilitate a pharmacological approach to the study of platelets by enabling concentration-response relationships to be defined quickly and easily. Estimation of IC50, EC50 and Emax values from platelet concentration response data, as well as other more complex pharmacological analysis have been outlined by Hourani [7] . Any attempts at compound screening and medicinal chemistry must include such pharmacological characterisation of compounds. Finally, high throughput methodologies facilitate testing of many different combinations of biologically active compounds, and therefore have many practical applications in research.
4.
Heated Images should be captured in the centre of every well and exported as an image series to simplify analysis 5.
Many different image analysis packages are available and the exact method to identify, count and measure individual platelets will vary but usually involves:
A) creating a 'threshold' that identifies platelets on the basis of fluorescence intensity (see note 2) and can be used to calculate % surface coverage which is the simplest output from the spreading assay ( figure 1) B) using the binary image generated by the 'threshold' to perform object or particle measurements, whereby characteristics of platelets (such as number and spread area) are quantified (Figure 2A Agonist injection speed should therefore be set to a high setting to achieve complete mixing. 
